Abstract：
:Artificial liver-support devices attempt to bridge patients with fulminant hepatic failure until either a suitable liver allograft is obtained for transplantation or the patient's own liver regenerates sufficiently to resume normal function. It is thought that toxins contribute to the clinical picture of fulminant hepatic failure. The earliest reports of successful toxin removal were blood- and plasma-exchange transfusions. Given these successful case reports, mechanical liver-support devices were designed to filter toxins. These mechanical devices used hemodialysis, charcoal hemoperfusion, hemoperfusion through cation-exchange resins, hemodiabsorption, and combinations of all of these techniques as in the MARS liver-support device. Despite promising case reports and small series, no controlled studies of mechanical devices have ever showed a long-term survival benefit. Thus, the removal of presumed toxins seems to be insufficient to support patients with fulminant hepatic failure, and the biologic function of the liver must also be replaced. Attempts at replacing the biologic function have included extracorporeal liver perfusion, cross-circulation, and hepatocyte transplantation. Current technologies have combined mechanical and biologic support systems in hybrid liver-support devices. The mechanical component of these hybrid devices serves both to remove toxins and to create a barrier between the patient's serum and the biologic component of the liver-support device. The biologic component of these hybrid liver support devices may consist of liver slices, granulated liver, or hepatocytes from low-grade tumor cells or porcine hepatocytes. These biologic components are housed within bioreactors. Currently the most clinically studied bioreactors are those that use capillary hollow-fiber systems. Both the bioartificial liver by Demetrious and the extracorporeal liver-assist device by Sussman and Kelly are in clinical trials. Although the trials seemed to have yielded good survival data when the devices are used as a bridge to transplantation, the type and degree of liver support provided by these devices remains uncertain. Thus, despite decades of great progress in the field of artificial liver support, no one technique alone yet provides sufficient liver support. A hybrid system seems to be the best option at present. Still to be determined is the best tissue to use, how much liver tissue should be used, and the optimal design of the bioreactor.
journal_name
Clin Liver Disjournal_title
Clinics in liver diseaseauthors
Sechser A,Osorio J,Freise C,Osorio RWdoi
10.1016/s1089-3261(05)70172-0subject
Has Abstractpub_date
2001-05-01 00:00:00pages
415-30issue
2eissn
1089-3261issn
1557-8224pii
S1089-3261(05)70172-0journal_volume
5pub_type
杂志文章,评审abstract：:Chronic hepatitis C virus (HCV) infection is the most common indication for liver transplantation in the United States and Europe, and more than 20,000 patients worldwide have undergone transplantation for complications of chronic hepatitis C. In North America, HCV accounts for 15% to 50% of the liver transplants perf...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/j.cld.2005.05.004
更新日期：2005-08-01 00:00:00
abstract：:Patients with hepatocellular carcinoma (HCC) have many treatment options. For patients with surgical indication, consideration of future liver remnant and the surgical complexity of the procedure is essential. A new 3-level complexity classification categorizing 11 liver resection procedures predicts surgical complexi...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/j.cld.2020.07.004
更新日期：2020-11-01 00:00:00
abstract：:Understanding of the pathogenesis of hepatic fibrosis on a molecular level has led to the identification of several putative serum markers of hepatic fibrosis. Either individually or in combination, these serum markers appear capable of determining early and advanced hepatic fibrosis. Radiological determination of hep...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/j.cld.2005.08.002
更新日期：2005-11-01 00:00:00
abstract：:Non-alcoholic fatty liver disease (NAFLD) is common and may progress to end-stage liver disease. Liver-related morbidity and mortality occur almost exclusively in patients whose disease progresses to advanced fibrosis and cirrhosis. Presence and severity of liver fibrosis seem the most important indicators of long-ter...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/j.cld.2007.02.004
更新日期：2007-02-01 00:00:00
abstract：:This article discusses direct-acting antiviral agents that target hepatitis C virus replication, their mechanism of action, strengths, and weaknesses. In addition, varying strategies using combinations of these agents are discussed. ...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/j.cld.2015.06.002
更新日期：2015-11-01 00:00:00
abstract：:Although there are no randomized, controlled trials evaluating the efficacy of endoscopic retrograde cholangiography (ERC) in primary sclerosing cholangitis (PSC) patients, substantial indirect evidence supports the effectiveness of ERC in symptomatic PSC patients with a dominant stricture. Currently, cumulative evide...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/j.cld.2014.07.013
更新日期：2014-11-01 00:00:00
abstract：:Liver cancer is the second leading cause of global cancer mortality. The major risk factors for hepatocellular carcinoma (HCC) are being addressed with success by prevention efforts. Vaccination against hepatitis B virus has reduced incidence of HCC in Taiwan and is partly responsible for lower rates in China. New inf...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/j.cld.2015.01.001
更新日期：2015-05-01 00:00:00
abstract：:Osteopenia, in the form of osteoporosis, is a common complication of chronic cholestatic liver diseases and, although its cause is poorly understood, it appears to be intimately related to the cholestasis itself. With more patients surviving longer with successful liver transplantation, the clinical significance of su...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/s1089-3261(05)70015-5
更新日期：1998-05-01 00:00:00
abstract：:Despite significant advances in nonsurgical treatments of hepatocellular carcinoma, these approaches rarely result in cure. Surgery remains the mainstay of curative therapy for hepatocellular carcinoma. Liver transplantation, in particular, has emerged as one of the most beneficial therapeutic modalities. Questions re...
journal_title：Clinics in liver disease
pub_type： 杂志文章
doi：10.1016/j.cld.2011.03.005
更新日期：2011-05-01 00:00:00
abstract：:Although hepatic encephalopathy (HE) is prevalent in the cirrhotic population, it has also been considered a potentially reversible condition. Liver transplantation represents the ultimate reversal of the decompensated cirrhotic state and should provide the best option for the reversibility of HE. However, the neurolo...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/j.cld.2011.12.004
更新日期：2012-02-01 00:00:00
abstract：:In the past two decades, pediatric liver transplantation has become the state-of-the-art operation with anticipated success and limited mortality. The future success of pediatric liver transplantation will require thoughtful solutions to the delicate balance of risk to donors and recipients, the complex needs of the a...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/j.cld.2005.10.004
更新日期：2006-02-01 00:00:00
abstract：:Transjugular intrahepatic portosystemic shunt (TIPS) is a well-established procedure used in the management of complications of portal hypertension. Although the most robust evidence supports the use of TIPS as salvage therapy in variceal hemorrhage, secondary prophylaxis of variceal bleeding, and treatment of refract...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/j.cld.2019.07.004
更新日期：2019-11-01 00:00:00
abstract：:Decision analysis helps evaluate competing strategies under conditions of uncertainty in a wide variety of clinical settings. Despite some limitations, decision trees and Markov models remain essential tools for medical decision analysts. These techniques allow comparison of competing management strategies in a quanti...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/j.cld.2004.12.004
更新日期：2005-05-01 00:00:00
abstract：:Combination therapy with beta-blockers and endoscopic band ligation (EBL) is the standard prophylaxis of esophageal variceal rebleeding in cirrhosis. Beta-blockers are the backbone of combination therapy, since their benefit extend to other complications of portal hypertension. EBL carries the risk of post-banding ulc...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/j.cld.2014.01.007
更新日期：2014-05-01 00:00:00
abstract：:Although several mouse models of AIH have been described, no model is ideal. Indeed, the disease is self-limited in each model, and none is associated with significant liver fibrosis or progression to cirrhosis. Nevertheless, these models should be useful for testing different hypotheses regarding the initiation of AI...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/s1089-3261(02)00026-0
更新日期：2002-08-01 00:00:00
abstract：:Liver dysfunction is common in both the critically ill and postoperative patient. Metabolic derangements secondary to sepsis, poor hepatic perfusion, total parenteral nutrition, in addition to hemodynamic and anesthetic-induced changes that occur during surgery, can cause liver damage ranging from small self-limited a...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/j.cld.2010.09.004
更新日期：2011-02-01 00:00:00
abstract：:A variety of benign and malignant neoplasms can be encountered in the liver. Hematoxylin and eosin-stained tissue sections alone may not yield sufficient information to definitively diagnose liver tumors; therefore, ancillary studies with immunohistochemical markers can play a crucial role in differentiating the diffe...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/j.cld.2010.10.001
更新日期：2010-11-01 00:00:00
abstract：:Since the introduction of small bowel capsule endoscopy, and more recently of esophageal capsule endoscopy, these diagnostic tools have become available for the evaluation of the consequences of portal hypertension in the esophagus, stomach, and small intestine. The main advantage of the esophageal and the small bowel...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/j.cld.2010.03.004
更新日期：2010-05-01 00:00:00
abstract：:This article reviews the spectrum of alcohol use disorders. The pharmacologic properties of ethanol and its metabolism, and the historical, physical, and laboratory elements that may help diagnose an alcohol use disorder are examined. The concepts of motivational interviewing and stages of change are mentioned, along ...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/j.cld.2012.08.006
更新日期：2012-11-01 00:00:00
abstract：:Abnormalities of LFTs and liver function occur not infrequently in patients with rheumatic conditions, and many diagnostic possibilities exist. Systemic inflammation that is related to uncontrolled rheumatic disease and periods of disease remission have been described as a cause for fluctuations in levels of serum ami...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/s1089-3261(02)00052-1
更新日期：2002-11-01 00:00:00
abstract：:Scientists and clinicians have made tremendous advances in understanding the pathogenesis of hepatitis C virus (HCV) infection and have developed impressive strategies for treating this hepatotropic virus in the short time since its discovery in 1989. This article goes beyond the current guidelines for the treatment o...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/j.cld.2006.08.024
更新日期：2006-11-01 00:00:00
abstract：:The causes of hepatic granulomas are numerous and their identification can be difficult. Sarcoidosis is a main cause of hepatic granulomas. The mechanisms that initiate the formation of sarcoid granulomas are unknown. This article discusses the pathology of hepatic sarcoidosis and hepatic granulomas. ...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/s1089-3261(05)70108-2
更新日期：2000-02-01 00:00:00
abstract：:Renal dysfunction is a frequent complication in patients with endstage liver disease awaiting orthotopic liver transplantation. Although the stereotypical form of renal dysfunction is the hepatorenal syndrome, common causes of acute kidney injury include prerenal azotemia and acute tubular necrosis in this population....
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/j.cld.2011.08.001
更新日期：2011-11-01 00:00:00
abstract：:Primary liver cancer is the fifth most common malignancy worldwide and the third leading cause of cancer mortality. Non-alcoholic fatty liver disease is the most common cause of chronic liver disease in the United States encompassing a spectrum of entities marked by hepatic steatosis in the absence of significant alco...
journal_title：Clinics in liver disease
pub_type： 杂志文章
doi：10.1016/j.cld.2009.07.007
更新日期：2009-11-01 00:00:00
abstract：:The DILI-sim Initiative is a public-private partnership using quantitative systems toxicology to build a model (DILIsym) capable of understanding and predicting liver safety liabilities in drug candidates. The effort has provided insights into mechanisms underlying dose-dependent drug-induced liver injury (DILI) and i...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/j.cld.2019.09.003
更新日期：2020-02-01 00:00:00
abstract：:Liver transplant (LT) is now an established indication for patients with chronic hepatitis B, mainly because of the development and use of hepatitis B immunoglobulin (HBIG) and oral antivirals for prophylaxis. The combination of low-dose HBIG and antivirals has been considered the standard prophylaxis regimen to preve...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/j.cld.2016.06.004
更新日期：2016-11-01 00:00:00
abstract：:Mathematical modeling of hepatitis C viral kinetics has been an important tool in understanding hepatitis C virus (HCV) infection dynamics and in estimating crucial in vivo parameters characterizing the effectiveness of HCV therapy. Because of the introduction of direct-acting antiviral agents, there is a need to exte...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/j.cld.2012.09.003
更新日期：2013-02-01 00:00:00
abstract：:Imaging and imaging guided intervention have revolutionized the management of hepatic inflammatory diseases. Pyogenic abscess is preferentially treated percutaneously. Radiologic techniques are crucial for the diagnosis of amebic liver abscess and infectious conditions of the liver in immunocompromised patients. ...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/s1089-3261(03)00073-4
更新日期：2002-02-01 00:00:00
abstract：:Bile acid synthetic defects are uncommon disorders that cause progressive cholestatic liver disease that is often lethal in infancy or early childhood. Five specific primary defects have been described. Diagnosis is based on mass spectrometry of urine and serum. Pathogenesis of liver injury is related to persistent re...
journal_title：Clinics in liver disease
pub_type： 杂志文章,评审
doi：10.1016/s1089-3261(05)70144-6
更新日期：2000-11-01 00:00:00
abstract：:The Model for End-stage Liver Disease (MELD) has been demonstrated to be an excellent predictor of survival in patients who have end-stage liver disease. It is derived from the international normalized ratio (INR) of prothrombin time, serum creatinine, and serum total bilirubin. The major use of the MELD score is to p...
journal_title：Clinics in liver disease
pub_type： 杂志文章
doi：10.1016/j.cld.2008.09.001
更新日期：2009-02-01 00:00:00
